Self-Report for Measuring and Predicting Medication Adherence: Experts’ Experience in Predicting Adherence in Stable Psychiatric Outpatients and in Pharmacokinetics

References

• De Las Cuevas C. Towards a clarification of terminology in medicine taking behavior: compliance, adherence and concordance are related although different terms with different uses. Curr Clin Pharmacol. 2011;6(2):74–77. doi:10.2174/157488411796151110
   PubMedGoogle Scholar
• Aronson JK. Compliance, concordance, adherence. Br J Clin Pharmacol. 2007;63(4):383–384. doi:10.1111/j.1365-2125.2007.02893.x
   PubMed Web of Science ®Google Scholar
• Kelley M. Limits on patient responsibility. J Med Philos. 2005;30(2):189–206. doi:10.1080/03605310590926858
   Web of Science ®Google Scholar
• Sabaté E. Adherence to Long-Term Therapies: Evidence for Action. Geneva (Switzerland): World Health Organization; 2003.
   Google Scholar
• Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry. 2012;200(2):97–106. doi:10.1192/bjp.bp.111.096594
   PubMed Web of Science ®Google Scholar
• Chapman SC, Horne R. Medication nonadherence and psychiatry. Curr Opin Psychiatry. 2013;26(5):446–452. doi:10.1097/YCO.0b013e3283642da4
   PubMed Web of Science ®Google Scholar
• Bulloch AG, Patten SB. Non-adherence with psychotropic medications in the general population. Soc Psychiatry Psychiatr Epidemiol. 2010;45(1):47–56. doi:10.1007/s00127-009-0041-5
   PubMed Web of Science ®Google Scholar
• Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008;8(1):32. doi:10.1186/1471-244X-8-32
   PubMed Web of Science ®Google Scholar
• San L, Bernardo M, Gómez A, Martínez P, González B, Peña M. Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients. Nord J Psychiatry. 2013;67(1):22–29. doi:10.3109/08039488.2012.667150
   PubMed Web of Science ®Google Scholar
• Witt K, van Dorn R, Fazel S, Zhang XY. Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. PLoS One. 2013;8(2):e55942. doi:10.1371/journal.pone.0055942
   PubMed Web of Science ®Google Scholar
• Lindström E, Eriksson L, Levander S. Suicides during 7 years among a catchment area cohort of patients with psychoses. Nord J Psychiatry. 2012;66(1):8–13. doi:10.3109/08039488.2011.577186
   PubMed Web of Science ®Google Scholar
• Ruengorn C, Sanichwankul K, Niwatananun W, Mahatnirunkul S, Pumpaisalchai W, Patumanond J. A risk-scoring scheme for suicide attempts among patients with bipolar disorder in a Thai patient cohort. Psychol Res Behav Manag. 2012;5:37–45. doi:10.2147/PRBM.S30878
   Google Scholar
• Cullen BA, McGinty EE, Zhang Y, et al. Guideline-concordant antipsychotic use and mortality in schizophrenia. Schizophr Bull. 2013;39(5):1159–1168. doi:10.1093/schbul/sbs097
   Web of Science ®Google Scholar
• Joe S, Lee JS. Association between non-compliance with psychiatric treatment and non-psychiatric service utilization and costs in patients with schizophrenia and related disorders. BMC Psychiatry. 2016;16(1):444. doi:10.1186/s12888-016-1156-3
   PubMed Web of Science ®Google Scholar
• Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982. doi:10.1136/bmjopen-2017-016982
   PubMed Web of Science ®Google Scholar
• Schwab AP. The epistemic responsibilities in medicine of beneficence and respect for patient autonomy. Ethics Med Public Health. 2017;3(2):233–240. doi:10.1016/j.jemep.2017.04.015
   Google Scholar
• Almanza M, Romero-Mendoza M, San Luis AG. The process of adherence to treatment in people living with HIV, in “advances in HIV and AIDS control”. IntechOpen. 2018. doi:10.5772/intechopen.77032
   Google Scholar
• Kessler RC, Berglund PA, Bruce ML, et al. The prevalence and correlates of untreated serious mental illness. Health Serv Res. 2001;36(6 Pt 1):987–1007.
   PubMed Web of Science ®Google Scholar
• Owiti J, Bowers L. A Literature Review: Refusal of Psychotropic Medication in Acute Inpatient Psychiatric Care. Report from the Conflict and Containment Reduction Research Program. London (United Kingdom): Institute of Psychiatry; 2010.
   Google Scholar
• Yalamova IV. Post-discharge medication adherence in schizophrenia. Arch Psychiatry Psychother. 2015;17(4):39–47. doi:10.12740/APP/60513
   Google Scholar
• Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927–942. doi:10.1176/appi.ajp.2017.16121358
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071. doi:10.1016/S0140-6736(12)60239-6
   PubMed Web of Science ®Google Scholar
• Grande I, Vieta E. Pharmacotherapy of acute mania: monotherapy or combination therapy with mood stabilizers and antipsychotics? CNS Drugs. 2015;29(3):221–227. doi:10.1007/s40263-015-0235-1
   PubMed Web of Science ®Google Scholar
• Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):351–359. doi:10.1016/S2215-0366(14)70314-1
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. doi:10.1016/S0140-6736(17)32802-7
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly EJ, Drevets WC. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants. Adv Pharmacol. 2020;89:237–259. doi:10.1016/bs.apha.2020.05.002
   Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46. doi:10.4088/JCP.7090su1cj
   PubMed Web of Science ®Google Scholar
• Tham XC, Xie H, Chng CM, Seah XY, Lopez V, Klainin-Yobas P. Factors affecting medication adherence among adults with schizophrenia: a literature review. Arch Psychiatr Nurs. 2016;30(6):797–809. doi:10.1016/j.apnu.2016.07.007
   PubMed Web of Science ®Google Scholar
• Kikkert MJ, Dekker J. Medication adherence decisions in patients with schizophrenia. Prim Care Companion CNS Disord. 2017;19(6). doi:10.4088/PCC.17n02182
   Google Scholar
• Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2019;80(5). doi:10.4088/JCP.IN18031AH1C
   Web of Science ®Google Scholar
• Bright CE. Measuring medication adherence in patients with schizophrenia: an integrative review. Arch Psychiatr Nurs. 2017;31(1):99–110. doi:10.1016/j.apnu.2016.09.003
   PubMed Web of Science ®Google Scholar
• Weiden PJ. Redefining medication adherence in the treatment of schizophrenia: how current approaches to adherence lead to misinformation and threaten therapeutic relationships. Psychiatr Clin North Am. 2016;39(2):199–216. doi:10.1016/j.psc.2016.01.004
   PubMed Web of Science ®Google Scholar
• McCutcheon R, Beck K, D’Ambrosio E, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand. 2018;137(1):39–46. doi:10.1111/acps.12825
   PubMed Web of Science ®Google Scholar
• Levin JB, Krivenko A, Howland M, Schlachet R, Sajatovic M. Medication adherence in patients with bipolar disorder: a comprehensive review. CNS Drugs. 2016;30(9):819–835. doi:10.1007/s40263-016-0368-x
   PubMed Web of Science ®Google Scholar
• MacDonald L, Chapman S, Syrett M, Bowskill R, Horne R. Improving medication adherence in bipolar disorder: A systematic review and meta-analysis of 30 years of intervention trials. J Affect Disord. 2016;194:202–221. doi:10.1016/j.jad.2016.01.002
   PubMed Web of Science ®Google Scholar
• Hartung D, Low A, Jindai K, et al. Interventions to improve pharmacological adherence among adults with psychotic spectrum disorders and bipolar disorder: a systematic review. Psychosomatics. 2017;58(2):101–112. doi:10.1016/j.psym.2016.09.009
   Web of Science ®Google Scholar
• Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127–134. doi:10.1080/13696998.2017.1379412
   PubMed Web of Science ®Google Scholar
• Boyce P, Irwin L, Morris G, et al. Long-acting injectable antipsychotics as maintenance treatments for bipolar disorder-A critical review of the evidence. Bipolar Disord. 2018;20(Suppl 2):25–36. doi:10.1111/bdi.12698
   PubMed Web of Science ®Google Scholar
• Gentile S. Discontinuation rates during long-term, second-generation antipsychotic long-acting injection treatment: A systematic review. Psychiatry Clin Neurosci. 2019;73(5):216–230. doi:10.1111/pcn.12824
   PubMed Web of Science ®Google Scholar
• Hung CI. Factors predicting adherence to antidepressant treatment. Curr Opin Psychiatry. 2014;27(5):344–349. doi:10.1097/YCO.0000000000000086
   PubMed Web of Science ®Google Scholar
• Rush AJ, Thase ME. Improving depression outcome by patient-centered medical management. Am J Psychiatry. 2018;175(12):1187–1198. doi:10.1176/appi.ajp.2018.18040398
   Web of Science ®Google Scholar
• Whalley Buono E, Vrijens B, Bosworth HB, Liu LZ, Zullig LL, Granger BB. Coming full circle in the measurement of medication adherence: opportunities and implications for health care. Patient Prefer Adherence. 2017;11:1009–1017. doi:10.2147/PPA.S127131
   Web of Science ®Google Scholar
• De Las Cuevas C, Peñate W, Sanz EJ. Psychiatric outpatients’ self-reported adherence versus psychiatrists’ impressions on adherence in affective disorders. Hum Psychopharmacol. 2013;28(2):142–150. doi:10.1002/hup.2293
   Web of Science ®Google Scholar
• De Las Cuevas C, Motuca M, Baptista T, de Leon J. Skepticism and pharmacophobia toward medication may negatively impact adherence to psychiatric medications: A comparison among outpatient samples recruited in Spain, Argentina, and Venezuela. Patient Prefer Adherence. 2018;12:301–310. doi:10.2147/PPA.S133513
   PubMed Web of Science ®Google Scholar
• De Las Cuevas C, Motuca M, Baptista T, Villasante-Tezanos AG, de Leon J. Ethnopsychopharmacology study of patients’ beliefs regarding concerns about and necessity of taking psychiatric medications. Hum Psychopharmacol. 2019;34(2):e2688. doi:10.1002/hup.2688
   Web of Science ®Google Scholar
• Velligan DI, Maples NJ, Pokorny JJ, Wright C. Assessment of adherence to oral antipsychotic medications: what has changed over the past decade? Schizophr Res. 2020;215:17–24. doi:10.1016/j.schres.2019.11.022
   Web of Science ®Google Scholar
• Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5(4):470–482. doi:10.1007/s13142-015-0315-2
   PubMed Web of Science ®Google Scholar
• Sidorkiewicz S, Tran VT, Cousyn C, Perrodeau E, Ravaud P. Development and validation of an instrument to assess treatment adherence for each individual drug taken by a patient. BMJ Open. 2016;6(5):e010510. doi:10.1136/bmjopen-2015-010510
   PubMed Web of Science ®Google Scholar
• De Las Cuevas C, Peñate W, Manuel García de Cecilia J, de Leon J. Predictive validity of the Sidorkiewicz instrument in Spanish: assessing individual drug adherence in psychiatric patients. Int J Clin Health Psychol. 2018;18(2):133–142. doi:10.1016/j.ijchp.2017.11.003
   Web of Science ®Google Scholar
• De Las Cuevas C, de Leon J. Development and validation of the patient’s health belief questionnaire on psychiatric treatment. Patient Prefer Adherence. 2019;10(13):527–536. doi:10.2147/PPA.S201144
   Web of Science ®Google Scholar
• De Las Cuevas C, Betancort M, de Leon J. The necessity-concern framework in the assessment of treatment adherence of psychiatric patients and the role of polypharmacy in a Spanish sample. Hum Psychopharmacol. 2020;35(1):e2721. doi:10.1002/hup.2721
   Web of Science ®Google Scholar
• Tang CT, Chua EC, Chew QH, et al. Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region. Asia Pac Psychiatry. 2020;29:e12393. doi:10.1111/appy.12393
   Web of Science ®Google Scholar
• Bobrovitz N, Heneghan C, Onakpoya I, et al. Medications that reduce emergency hospital admissions: an overview of systematic reviews and prioritisation of treatments. BMC Med. 2018;16(1):115. doi:10.1186/s12916-018-1104-9
   Web of Science ®Google Scholar
• Corring D, O’Reilly RL, Sommerdyk C, Russell E. What clinicians say about the experience of working with individuals on community treatment orders. Psychiatr Serv. 2018;69(7):791–796. doi:10.1176/appi.ps.201700492
   Web of Science ®Google Scholar
• Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274–280. doi:10.1016/j.schres.2017.12.010
   PubMed Web of Science ®Google Scholar
• Irwin M. Theoretical foundations of adherence behaviors: synthesis and application in adherence to oral oncology agents. Clin J Oncol Nurs. 2015;19(3 Suppl):31–35. doi:10.1188/15.S1.CJON.31-35
   Web of Science ®Google Scholar
• Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–468. doi:10.2147/PPA.S124658
   PubMed Web of Science ®Google Scholar
• De Las Cuevas C, Sanz EJ. Attitudes toward psychiatric drug treatment: the experience of being treated. Eur J Clin Pharmacol. 2007;63(11):1063–1067. doi:10.1007/s00228-007-0358-5
   Web of Science ®Google Scholar
• Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic medication non-adherence and associated factors among adult patients with major psychiatric disorders: a protocol for a systematic review. Syst Rev. 2018;7(1):10. doi:10.1186/s13643-018-0676-y
   PubMed Web of Science ®Google Scholar
• Rivero-Santana A, Perestelo-Perez L, Pérez-Ramos J, Serrano-Aguilar P, De Las Cuevas C. Sociodemographic and clinical predictors of compliance with antidepressants for depressive disorders: systematic review of observational studies. Patient Prefer Adherence. 2013;7:151–169. doi:10.2147/PPA.S39382
   Web of Science ®Google Scholar
• Sendt KV, Tracy DK, Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015;225(1–2):14–30. doi:10.1016/j.psychres.2014.11.002
   PubMed Web of Science ®Google Scholar
• Edgcomb JB, Zima B. Medication adherence among children and adolescents with severe mental illness: a systematic review and meta-analysis. J Child Adolesc Psychopharmacol. 2018;28(8):508–520. doi:10.1089/cap.2018.0040
   Web of Science ®Google Scholar
• García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016;36(4):355–371. doi:10.1097/JCP.0000000000000523
   PubMed Web of Science ®Google Scholar
• Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol. 2015;25(8):1158–1166. doi:10.1016/j.euroneuro.2015.04.003
   PubMed Web of Science ®Google Scholar
• Horne R. The Nature, Determinants and Effects of Medication Beliefs in Chronic Illness [PhD thesis]. University of London; 1997.
   Google Scholar
• Rosenstock IM. Historical origins of the health belief model. Health Educ Monogr. 1974;2(4):328–335. doi:10.1177/109019817400200403
   Google Scholar
• Jones CJ, Smith H, Llewellyn C. Evaluating the effectiveness of health belief model interventions in improving adherence: a systematic review. Health Psychol Rev. 2014;8(3):253–269. doi:10.1080/17437199.2013.802623
   PubMed Web of Science ®Google Scholar
• Sulat J, Prabandari Y, Sanusi R, Hapsari E, Santoso B. The validity of health belief model variables in predicting behavioral change: a scoping review. Health Educ. 2018;118(6):499–512. doi:10.1108/HE-05-2018-0027
   Web of Science ®Google Scholar
• Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177–183. doi:10.1017/s0033291700050182
   PubMed Web of Science ®Google Scholar
• De Las Cuevas C, de Leon J. A clinimetric approach for improving the measurement of pharmacophobia with replication in two other samples. Psychother Psychosom. 2019;88(2):116–118. doi:10.1159/000495940
   Web of Science ®Google Scholar
• Brain C, Allerby K, Sameby B, et al. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study. Eur Neuropsychopharmacol. 2013;3(12):1754–1762. doi:10.1016/j.euroneuro.2013.09.001
   Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909. doi:10.4088/jcp.v63n1007
   PubMed Web of Science ®Google Scholar
• Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005;62(7):717–724. doi:10.1001/archpsyc.62.7.717
   PubMed Web of Science ®Google Scholar
• Moritz S, Peters MJ, Karow A, Deljkovic A, Tonn P, Naber D. Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients. Ment Ill. 2009;1(1):4–9. doi:10.4081/mi.2009.e2
   Google Scholar
• De Las Cuevas C, Peñate W. Explaining pharmacophobia and pharmacophilia in psychiatric patients: relationship with treatment adherence. Hum Psychopharmacol. 2015;30(5):377–383. doi:10.1002/hup.2487
   Web of Science ®Google Scholar
• De Las Cuevas C, Peñate W, Sanz EJ. Risk factors for non-adherence to antidepressant treatment in patients with mood disorders. Eur J Clin Pharmacol. 2014;70(1):89–98. doi:10.1007/s00228-013-1582-9
   PubMed Web of Science ®Google Scholar
• Wallston KA, Stein MJ, Smith CA. Form C of the MHLC scales: a condition-specific measure of locus of control. J Pers Assess. 1994;63(3):534–553. doi:10.1207/s15327752jpa6303_10
   PubMed Web of Science ®Google Scholar
• Wallston KA, Wallston BS. Who is responsible for your health? The construct of health locus of control. In: Sanders G, Suls J, editors. Social Psychology of Health and Illness. Hillsdale (NJ): Lawrence Erlbaum and Associates; 1982.
   Google Scholar
• Wallston KA. Assessment of control in health-care settings. In: Steptoe A, Apples A, editors. Stress, Personal Control and Health. New York: John Wiley & Son; 1989.
   Google Scholar
• Nazareth M, Richards J, Javalkar K, et al. Relating health locus of control to health care use, adherence, and transition readiness among youths with chronic conditions, North Carolina, 2015. Prev Chronic Dis. 2016;21:13:E93. doi:10.5888/pcd13.160046
   Web of Science ®Google Scholar
• De Las Cuevas C, Peñate W, Cabrera C. Perceived health control: a promising step forward in our understanding of treatment adherence in psychiatric care. J Clin Psychiatry. 2016;77:e1233–e1239. doi:10.4088/JCP.15m09769
   Web of Science ®Google Scholar
• Rosenberg BD, Siegel JT. A 50-year review of psychological reactance theory: do not read this article. Motiv Sci. 2017;4(4):281–300. doi:10.1037/mot0000091
   Google Scholar
• Reynolds-Tylus T. Psychological reactance and persuasive health communication: a review of the literature. Front Commun. 2019;4(56):1–12. doi:10.3389/fcomm.2019.00056
   Google Scholar
• Brehm JW. A Theory of Psychological Reactance. New York, NY: Academic Press; 1966.
   Google Scholar
• Steindl C, Jonas E, Sittenthaler S, Traut-Mattausch E, Greenberg J. Understanding psychological reactance: new developments and findings. Z Psychol. 2015;223(4):205–214. doi:10.1027/2151-2604/a000222
   PubMed Web of Science ®Google Scholar
• Hong S-M, Faedda S. Refinement of the Hong psychological reactance scale. Educ Psychol Meas. 1996;56(1):173–182. doi:10.1177/0013164496056001014
   Web of Science ®Google Scholar
• De Las Cuevas C, Peñate W, Betancort M, de Rivera L. Psychological reactance in psychiatric patients: examining the dimensionality and correlates of the Hong psychological reactance scale in a large clinical sample. Pers Individ Dif. 2014;70:85–91. doi:10.1016/j.paid.2014.06.027
   Web of Science ®Google Scholar
• De Las Cuevas C, Peñate W, Sanz EJ. The relationship of psychological reactance, health locus of control and sense of self-efficacy with adherence to treatment in psychiatric outpatients with depression. BMC Psychiatry. 2014;14(1):324. doi:10.1186/s12888-014-0324-6
   PubMed Web of Science ®Google Scholar
• Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework. PLoS One. 2013;8(12):e80633. doi:10.1371/journal.pone.0080633
   PubMed Web of Science ®Google Scholar
• Phillips LA, Diefenbach MA, Kronish IM, Negron RM, Horowitz CR. The necessity-concerns framework: a multidimensional theory benefits from multidimensional analysis. Ann Behav Med. 2014;48(1):7–16. doi:10.1007/s12160-013-9579-2
   PubMed Web of Science ®Google Scholar
• Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1–24. doi:10.1080/08870449908407311
   Web of Science ®Google Scholar
• Aikens JE, Nease DE Jr, Nau DP, Klinkman MS, Schwenk TL. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med. 2005;3(1):23–30. doi:10.1370/afm.238
   PubMed Web of Science ®Google Scholar
• Menckeberg TT, Bouvy ML, Bracke M, et al. Beliefs about medicines predict refill adherence to inhaled corticosteroids. J Psychosom Res. 2008;64(1):47–54. doi:10.1016/j.jpsychores.2007.07.016
   PubMed Web of Science ®Google Scholar
• Chang DS, Kang OS, Kim HH, et al. Pre-existing beliefs and expectations influence judgments of novel health information. J Health Psychol. 2012;17(5):753–763. doi:10.1177/1359105311421044
   Web of Science ®Google Scholar
• Dolovich L, Nair K, Sellors C, Lohfeld L, Lee A, Levine M. Do patients’ expectations influence their use of medications? Qualitative study. Can Fam Physician. 2008;54(3):384–393.
   PubMed Web of Science ®Google Scholar
• De Las Cuevas C, Peñate W, Betancort M, Cabrera C. What do psychiatric patients believe regarding where control over their illness lies? Validation of the multidimensional health locus of control scale in psychiatric outpatient care. J Nerv Ment Dis. 2015;203(2):81–86. doi:10.1097/NMD.0000000000000244
   PubMed Web of Science ®Google Scholar
• de Leon J. A critical commentary on the 2017 AGNP consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. Pharmacopsychiatry. 2018;51(1–2):63–68. doi:10.1055/s-0043-117891
   Web of Science ®Google Scholar
• de Leon J. Pharmacogenetic tests in psychiatry: from fear to failure to hype. J Clin Psychopharmacol. 2016;36(4):299–304. doi:10.1097/JCP.0000000000000522
   PubMed Web of Science ®Google Scholar
• de Leon J. Why do you keep telling me that drug-drug interactions are important in psychopharmacology when I do not see them in my clinical practice?: my failure to convince clinicians. J Clin Psychopharmacol. 2019;39(1):1–4. doi:10.1097/JCP.0000000000000924
   PubMed Web of Science ®Google Scholar
• de Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res. 2009;59(2):81–89. doi:10.1016/j.phrs.2008.10.002
   PubMed Web of Science ®Google Scholar
• de Leon J. Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics. Neuropharmacology. 2020;168:107656. doi:10.1016/j.neuropharm.2019.05.033
   PubMed Web of Science ®Google Scholar
• de Leon J, Ruan CJ, Schoretsanitis G, De Las Cuevas C. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom. 2020;89(4):200–214. doi:10.1159/000507638
   PubMed Web of Science ®Google Scholar
• Verghese C, De Leon J, Nair C, Simpson GM. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry. 1996;39(2):135–138. doi:10.1016/0006-3223(95)00215-4
   Web of Science ®Google Scholar
• de Leon J, Henighan V, Stanilla JK, Simpson GM. Clozapine levels after clozapine discontinuation. J Clin Psychopharmacol. 1996;16(2):193–194. doi:10.1097/00004714-199604000-00016
   Web of Science ®Google Scholar
• de Leon J, Stanilla JK, White AO, Simpson GM. Anticholinergics to treat clozapine withdrawal. J Clin Psychiatry. 1994;55(3):119–120.
   Web of Science ®Google Scholar
• Stanilla JK, de Leon J, Simpson GM. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. J Clin Psychiatry. 1997;58(6):252–255. doi:10.4088/jcp.v58n0603
   Web of Science ®Google Scholar
• Bilbily J, McCollum B, de Leon J. Catatonia secondary to sudden clozapine withdrawal: a case with three repeated episodes and a literature review. Case Rep Psychiatry. 2017;2017:2402731. doi:10.1155/2017/2402731
   Google Scholar
• Bauer LA. Clinical Pharmacokinetics Handbook. New York, NY: McGraw-Hill; 2006.
   Google Scholar
• Fang J, Mosier KE. Literature values of terminal half-lives of clozapine are dependent on the time of the last data point. J Pharm Pharm Sci. 2014;17(2):187. doi:10.18433/j3kc7p
   Web of Science ®Google Scholar
• Inc S. Clozapine-clozapine tablet. Highlights of prescribing information. Princeton, NJ:Sandoz Inc; 2020. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e503b3cd-574e-ed6a-c7ed-3368115f7f72. Accessed September 28, 2020.
   Google Scholar
• Diaz FJ, Josiassen RC, de Leon J. The effect of body weight changes on total plasma clozapine concentrations determined by applying a statistical model to the data from a double-blind trial. J Clin Psychopharmacol. 2018;38(5):442–446. doi:10.1097/JCP.0000000000000926
   PubMed Web of Science ®Google Scholar
• Ruan CJ, de Leon J. Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine? Pharmacogenomics. 2020;21(6):369–373. doi:10.2217/pgs-2020-0015
   PubMed Web of Science ®Google Scholar
• de Leon J, Schoretsanitis G, Kane JM, Ruan CJ. Using therapeutic drug monitoring to personalize clozapine dosing in Asians. Asia Pac Psychiatry. 2020;12(2):e12384. doi:10.1111/appy.12384
   PubMed Web of Science ®Google Scholar
• Ruan CJ, Wang CY, Tang YL, et al. Exploring the prevalence of clozapine phenotypic poor metabolizers in 4 Asian samples: they ranged between 2% and 13. J Clin Psychopharmacol. 2019;39(6):644–648. doi:10.1097/JCP.0000000000001125
   PubMed Web of Science ®Google Scholar
• de Leon J, De Las Cuevas C. The art of pharmacotherapy: reflections on pharmacophobia. J Clin Psychopharmacol. 2017;37(2):131–137. doi:10.1097/JCP.0000000000000675
   Web of Science ®Google Scholar
• Konstantakopoulos G. Insight across mental disorders: a multifaceted metacognitive phenomenon. Psychiatriki. 2019;30(1):13–16. doi:10.22365/jpsych.2019.301.13
   Google Scholar
• Kim J, Ozzoude M, Nakajima S, et al. Insight and medication adherence in schizophrenia: an analysis of the CATIE trial. Neuropharmacology. 2020;168:107634. doi:10.1016/j.neuropharm.2019.05.011
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Rojas L, Martínez-Ortega JM, Pérez-Costillas L, Jiménez-Fernández S, Carretero MD, Gurpegui M. Illness insight and medication adherence among patients with bipolar disorder. J Nerv Ment Dis. 2020;208(6):481–487. doi:10.1097/NMD.0000000000001151
   Web of Science ®Google Scholar
• Bell M, Fiszdon J, Richardson R, Lysaker P, Bryson G. Are self-reports valid for schizophrenia patients with poor insight? Relationship of unawareness of illness to psychological self-report instruments. Psychiatry Res. 2007;151(1–2):37–46. doi:10.1016/j.psychres.2006.04.012
   PubMed Web of Science ®Google Scholar
• Buckwalter KC, Kerfoot KM. Teaching patients self care: a critical aspect of psychiatric discharge planning. J Psychosoc Nurs Ment Health Serv. 1982;20(5):15–20.
   Google Scholar
• Alghzawi HM. Psychiatric discharge process. ISRN Psychiatry. 2012;638943. doi:10.5402/2012/638943
   Google Scholar
• Smith RL, O’Connell K, Athanasiu L, et al. Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients-a genome-wide association study adjusting for smoking habits. Transl Psychiatry. 2020;10(1):198. doi:10.1038/s41398-020-00888-1
   Web of Science ®Google Scholar
• Schoretsanitis G, Kane JM, Ruan CJ, Spina E, Hiemke C, de Leon J. A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Rev Clin Pharmacol. 2019;12(7):603–621. doi:10.1080/17512433.2019.1617695
   PubMed Web of Science ®Google Scholar
• Kyllesø L, Smith RL, Ø K, Andreassen OA, Molden E. Undetectable or subtherapeutic serum levels of antipsychotic drugs preceding switch to clozapine. NPJ Schizophr. 2020;6(1):17. doi:10.1038/s41537-020-0107-7
   PubMed Web of Science ®Google Scholar
• Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37(6):243–265. doi:10.1055/s-2004-832687
   PubMed Web of Science ®Google Scholar
• Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–2):e1. doi:10.1055/s-0037-1600991
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Kane JM, Correll CU, et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American society of clinical psychopharmacology and the therapeutic drug monitoring task force of the arbeitsgemeinschaft für neuropsychopharmakologie und pharmakopsychiatrie. J Clin Psychiatry. 2020;81(3):19cs13169. doi:10.4088/JCP.19cs13169
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Spina E, Hiemke C, de Leon J. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol. 2017;10(9):965–981. doi:10.1080/17512433.2017.1345623
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Spina E, Hiemke C, de Leon J. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Rev Clin Pharmacol. 2018;11(6):625–639. doi:10.1080/17512433.2018.1478727
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Spina E, Hiemke C, de Leon J. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Rev Clin Pharmacol. 2018;11(12):1237–1253. doi:10.1080/17512433.2018.1549489
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Villasante-Tezanos AG, de Leon J. Studies of half lives of long-acting antipsychotics are needed. Pharmacopsychiatry. 2019;52(1):45–46. doi:10.1055/a-0755-7692
   Web of Science ®Google Scholar
• Chopra N, Ruan CJ, McCollum B, Ognibene J, Shelton C, de Leon J. High doses of drugs extensively metabolized by CYP3A4 were needed to reach therapeutic concentrations in two patients taking inducers. Rev Colomb Psiquiatr. 2020;49(2):84–95. doi:10.1016/j.rcp.2018.07.002
   Google Scholar
• Horvitz-Lennon M, Mattke S, Predmore Z, Howes OD. The role of antipsychotic plasma levels in the treatment of schizophrenia. Am J Psychiatry. 2017;174(5):421–426. doi:10.1176/appi.ajp.2016.16040402
   Web of Science ®Google Scholar
• Kalaria SN, Kelly DL. Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes. Neuropsychiatr Dis Treat. 2019;15:2365–2370. doi:10.2147/NDT.S216803
   PubMed Web of Science ®Google Scholar
• Cohen AN, Collins G, Nucifora FC Jr, Strobel R, Wait DB, Young AS. Clinical consensus recommendations for urine testing of adherence to antipsychotics among people with serious mental illness. Psychiatr Serv. 2018;69(3):345–348. doi:10.1176/appi.ps.201700082
   Web of Science ®Google Scholar
• Italiano D, Spina E, de Leon J. Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opin Drug Metab Toxicol. 2014;10(11):1457–1489. doi:10.1517/17425255.2014.956081
   PubMed Web of Science ®Google Scholar
• Lana F, Martí-Bonany J, Fuster J, de Leon J. Reduction in serum concentration of valproic acid secondary to the intake of ibuprofen as an example of valproic acid auto-induction metabolism. Actas Esp Psiquiatr. 2016;44(4):136–144.
   PubMed Web of Science ®Google Scholar
• Jackson J, McCollum B, Ognibene J, Diaz FJ, de Leon J. Three patients needing high doses of valproic acid to get therapeutic concentrations. Case Rep Psychiatry. 2015;2015:542862. doi:10.1155/2015/542862
   PubMedGoogle Scholar
• Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993;90(24):11825–11829. doi:10.1073/pnas.90.24.11825
   PubMed Web of Science ®Google Scholar
• Levanthal H, Brissette I, Levanthal EA. The common sense model of self-regulation of health and illness. In: Routledge, editor. The Self-Regulation of Health and Illness Behavior. London: Routledge; 2003:42–65.
   Google Scholar
• Unni EJ, Shiyanbola OO, Farris KB. Change in medication adherence and beliefs in medicines over time in older adults. Glob J Health Sci. 2016;8(5):39–47. doi:10.5539/gjhs.v8n5p39
   Google Scholar